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Abstract
Background: In order to compare the effectiveness of different antipsychotic drugs in the
treatment of schizophrenia it is very important to evaluate subjective response and compliance in
patient cohorts treated according to routine clinical practice.
Method: Outpatients with schizophrenia entered this prospective, naturalistic study when they
received a new prescription for an antipsychotic drug. Treatment assignment was based on purely
clinical criteria, as the study did not include any experimental intervention. Patients treated with
olanzapine, risperidone or haloperidol were included in the analysis. Subjective response was
measured using the 10-item version of the Drug Attitude Inventory (DAI-10), and treatment
compliance was measured using a physician-rated 4 point categorical scale.
Results: A total of 2128 patients initiated treatment (as monotherapy) with olanzapine, 417 with
risperidone, and 112 with haloperidol. Olanzapine-treated patients had significantly higher DAI-10
scores and significantly better treatment compliance compared to both risperidone- and
haloperidol-treated patients. Risperidone-treated patients had a significantly higher DAI-10 score
compared to haloperidol-treated patients.
Conclusion: Subjective response and compliance were superior in olanzapine-treated patients,
compared to patients treated with risperidone and haloperidol, in routine clinical practice.
Differences in subjective response were explained largely, but not completely, by differences in
incidence of EPS.
Background
Some patients with schizophrenia report experiencing
subjective sensations of change after only a few doses of
neuroleptic drugs. They often complain vaguely of not
feeling like themselves or somehow being limited in
terms of activity. It is not uncommon to hear expressions
like 'apathetic', 'mummified', ... [1] or to hear patients re-
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port that they are 'incapable of thinking straight' or feel
'like zombies' [2].
These complaints have been related to antipsycotic thera-
py, although not always specifically. The phenomenon
has received various names including pharmacogenic de-
pression [3], behavioural toxicity [4], subjective dysphoric
response [5,1], psychophysiological sensitivity [6,7], neu-
roleptic dysphoria' [8], neuroleptic anhedonia [9], and
neuroleptic depression [10].
We have chosen the term 'subjective response' coined by
Hogan et al [2]. Our feeling is that this term best reflects
the individual sensation experienced by patients in re-
sponse to antipsychotic treatment. According to Awad
[11], this subjective response is the subjective interpreta-
tion of physiological changes following the administra-
tion of medication.
Difficulty arises when one attempts to establish the mech-
anism behind the nature (positive or negative) and degree
of patient subjective response to medication. There does
not seem to be significant sociodemographic differences
between those patients with a good subjective response
and those with a poor response [12,13]. Some authors feel
that patient complaints may reflect extrapyramidal or au-
tonomic symptoms, particularly syndromes of akinesia
[14] or akathisia [15,7,16,17]. Further, a relationship has
been inferred between subjective response and patient at-
titudes towards health [18] or illness [19,20] or with the
presence of mood changes, mainly depression and organ-
ic depression [21,22]. There have also been attempts to re-
late the mesolimbic antidopaminergic action of
neuroleptic drugs to subjective response. Some authors
have maintained that subjective response is more likely to
be positive with atypical neuroleptics [23,24].
While opinions vary regarding the mechanism behind dif-
fering subjective responses to treatment, there is unanim-
ity when it comes to highlighting its clinical importance.
Although the impact of subjective response on treatment
compliance has been emphasised [13,25,26], subjective
response has also been identified as a prognostic and
linked to treatment response, quality of life, drug abuse,
and suicidality [26–28,17,29].
Given its clinical significance and impact on the global
outcome of treatment, it is obvious that attempts to deter-
mine the utility of new antipsychotics should include
measurement of subjective response. Unfortunately,
measuring subjective response is not an easy task. It is dif-
ficult to obtain externally valid results from clinical trials.
Schizophrenia treatment in the context of a clinical trial is
often substantially different from daily clinical practice.
Clinical trials usually exclude patients with a limited
awareness of their illness. In addition, schizophrenic pa-
tients who are substance abusers or who suffer with con-
comitant organic or psychiatric disorders, highly
prevalent conditions in the schizophrenic population
[30], are often excluded from clinical trials. Also, other
factors such as limitations on concomitant treatments and
greater control of compliance contribute to limit the gen-
eralizability of clinical trial results.
Naturalistic studies, on the other hand, provide a unique
opportunity to understand the nature of subjective re-
sponses to antipsychotic treatment that patients with
schizophrenia experience in the course of real-world treat-
ment. Subjective response to antipsychotic therapy was as-
sessed in the context of the largest prospective,
naturalistic, observational study of schizophrenia con-
ducted to date (the EFESO study). The main objective of
this analysis was to compare subjective response in pa-
tients with schizophrenia treated with olanzapine with
patients treated with other antipsychotics.
Method
EFESO was a prospective, comparative, observational,
naturalistic study conducted in Spain designed to assess
the safety of olanzapine when compared with other antip-
sychotic drugs in the treatment of outpatients with schiz-
ophrenia. The design and primary results of the study
have been described elsewhere [31]. Data were collected
on a total of 2967 patients, treated by 293 psychiatrists.
Patients were eligible for the study if they were diagnosed
with schizophrenia (F.20 of the ICD10). The only patients
excluded were those in whom antipsychotic drug therapy
was contraindicated, those in whom clozapine therapy
was indicated (restricted in Spain to patients with resistant
schizophrenia), and those participating in clinical trials.
Patients meeting entry criteria were enrolled upon receiv-
ing a new prescription of olanzapine or any other antipsy-
chotic drug and agreeing to participate in the study.
Physician treatment choice was by means of purely clini-
cal criteria, with no restrictions on the clinical handling of
patients and patients were not subject to experimental in-
tervention. To limit selection bias, investigators were in-
structed to include all patients who received a new
prescription of olanzapine or any other antipsychotic
drug, who met inclusion/exclusion criteria, and who
agreed to participate in the study until completing a block
of 6 patients treated with olanzapine and 3 patients treat-
ed with other antipsychotics. Once a block was complet-
ed, investigators could include additional blocks until
completion of the total sample. Selection of treatment
was the investigators choice; therefore bias in treatment
assignment could not be controlled.BMC Psychiatry 2001, 1 http://www.biomedcentral.com/1471-244X/1/7
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Data were collected over three visits: baseline (before re-
ceipt of their new antipsychotic prescription), after 3
months, and after 6 months of treatment. Patients discon-
tinued the study when the principal antipsychotic pre-
scribed at baseline was discontinued due to adverse
events, lack of efficacy, or any other reason.
Secondary objectives of the study were to assess subjective
response and compliance with antipsychotic treatment.
Subjective response was measured using the 10 item ver-
sion of the Drug Attitude Inventory (DAI) [2]. The DAI is
a self-report scale developed to measure subjective re-
sponses and attitudes of chronic schizophrenic patients
towards maintenance antipsychotic treatment. The origi-
nal version of the scale consists of 30 items covering seven
categories: subjective positive, subjective negative, health
and illness, physician control, prevention, and harm. A
shorter version consisting of 10 key items was subsequent-
ly developed (the DAI-10). These items are presented as
self-report statements with which the patient agrees or dis-
agrees. Each response is scored as +1 if correct or -1 if in-
correct. The final score is the grand total of the positive
and negative points. A positive total score means a posi-
tive subjective response. A negative total score means a
negative subjective response. The DAI-10 is concise, easy
to administer, and its psychometric properties are well es-
tablished. The scale has been shown to have test-retest re-
liability, high internal consistency, and discriminant,
predictive, and concurrent validity [13].
Compliance with principal antipsychotic treatment was
evaluated subjectively by the treating psychiatrist accord-
ing to the following scale: high (compliance with 80% of
doses), moderate (compliance with 60–79% of doses),
low (compliance with 20–59% of doses) and nil (compli-
ance with <20% of doses). Safety was evaluated through
the collection of spontaneous adverse events, and a specif-
ic questionnaire for extrapyramidal symptoms (EPS) de-
rived from the UKU scale [32], measuring dystonia,
akathisia, parkinsonism, dyskinesia, and other EPS. Glo-
bal clinical status was measured through the Clinical Glo-
bal Impression of Severity (CGI-S) and the Global
Assessment of Functioning (GAF) scales.
Statistical analyses
Analyses were conducted in accordance with the intent to
treat principle, such that data on all patients for whom in-
formation was available were included. Subjective re-
sponse and compliance were compared across treatment
groups that included at least 100 patients. Treatment
group comparisons were conducted among patients treat-
ed with olanzapine (n = 2,128), risperidone (n = 417),
and haloperidol (n = 112).
The primary hypotheses tested in this analysis was that pa-
tients treated with olanzapine would experience a better
subjective response to treatment and would be more com-
pliant compared to patients treated with risperidone or
haloperidol. A secondary hypothesis was that differences
in subjective response would not be solely driven by dif-
ferences in the incidence of extrapyramidal symptoms
across treatment groups. To test this hypothesis, we com-
pared subjective response across treatment groups after di-
viding the overall sample into two categories: patients
who exhibited treatment emergent EPS and those who did
not.
Analyses were conducted by visit, using an observed case
approach, and included patients treated with olanzapine,
risperidone or haloperidol who had a DAI-10 rating at
baseline, after three months of treatment, and after 6
months of treatment. The Wilcoxon test, the Chi square
test, and the Armitage test were used to compare mean
DAI-10 scores, the proportion of patients with a positive
subjective response, and the proportion of patients at dif-
ferent levels of compliance across treatment groups, re-
spectively.
Phoenix International carried out the statistical analyses.
The SAS® system, version 6.12 for Windows, was used for
verification, validation, and analyses of the data. All anal-
yses were post-hoc, and main effects were tested at a two-
sided a level of 0.05.
Results
Table 1 shows the baseline characteristics for the three
treatment groups compared in this analysis. The overall
average age was approximately 35 years and approximate-
ly 36% of the patients were female. There were no statisti-
cally significant differences in the mean ages or the gender
distributions between the three groups. The majority of
patients (around 65%) had a diagnosis of paranoid schiz-
ophrenia and the average time of disease duration was
about 10 years. There were no statistically significant dif-
ferences in the proportions of schizophrenia subtypes or
the mean disease duration between the three groups. With
respect to baseline severity of illness, the overall average
Clinical Global Impression (CGI-S) score was between 4
(moderately ill) and 5 (markedly ill), with small (though
statistically significant) differences between the groups.
Olanzapine-treated patients presented with a slightly
higher (more severe) mean CGI-S score than patients
treated with risperidone (p < 0.005) and with a lower
mean (less severe) CGI-S score than patients treated with
haloperidol (p < 0.05). The mean initial GAF score for
olanzapine-treated patients was also slightly lower (more
severe) than for patients treated with risperidone (p <
0.05) and higher (less severe) than for patients treated
with haloperidol (p < 0.005).BMC Psychiatry 2001, 1 http://www.biomedcentral.com/1471-244X/1/7
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The initial mean dose of olanzapine was 12.2 mg/day and
the overall mean dose was 13 mg/day. In the case of risp-
eridone, the initial and the overall mean doses were 5.2
and 5.4 mg/day, respectively. The initial and overall mean
doses of haloperidol were 13.9 and 13.6 mg/day, respec-
tively. The median doses (both initially and overall) were
10 mg/day for olanzapine, 6 mg/day for risperidone, and
10 mg/day for haloperidol.
Subjective response by treatment group as measured using
the DAI-10 is summarised in Table 2. All three treatment
groups had a positive subjective response to treatment.
Olanzapine-treated patients had a significantly better sub-
jective response at both the three and six month time
points compared to both risperidone- and haloperidol-
treated patients. Risperidone-treated patients had a signif-
icantly better subjective response to treatment at both the
three (p = 0.003) and six (p = 0.003) month time points
compared to haloperidol-treated patients.
The vast majority of patients had a positive subjective re-
sponse to treatment at both the three and six month time
points regardless of treatment group (see Table 3). A sig-
nificantly larger percentage of olanzapine-treated patients
Table 1: Baseline characteristics of the three treatment groups.
Olanzapine Risperidone Haloperidol
N = 2128 N = 417 N = 112 p-value
Age (years) 35.6 ± 11.7 34.4 ± 11.2 34.3 ± 10.4 NS
Sex (% females) 36.3 34.1 39.3 NS
Disease Duration (years) 11.1 ± 9.6 10.3 ± 9.0 9.5 ± 9.5 NS
Schizophrenia subtype
(%)
• Paranoid 64.7 65.1 72.3
• Undifferentiated 13.6 13.7 11.6
• Residual 12.8 11.8 5.4 NS
• Disorganized 8.4 8.4 10.7
• Catatonic 0.5 1.0 0.0
Baseline CGI-S 4.66 ± 0.91,2 4.53 ± 0.9 4.9 ± 0.91 1 p < 0.005 (RIS)
2 p < 0.050 (HAL)
Baseline GAF 44.9 ± 14.83,4 46.7 ± 14.6 40.7 ± 16.2 3 p < 0.050 (RIS)
4 p <0.005 (HAL)
Table 2: DAI-10 score by treatment group.
OLZ RIS HAL
Baseline Mean 0,17 0,32 -1,25*
SD 5,38 5,24 5,26
M e d i a n 000
N of observations 2028 394 102
3 months Mean 3,64 2,87** 1,31+
SD 4,66 4,87 4,98
M e d i a n 442
N of observations 1925 375 101
6 months Mean 4,63 3,42++ 1,68+
SD 4,34 4,97 5,2
M e d i a n 642
N of observations 1740 354 95
*p < 0,05 vs. OLZ and RIS; **p = 0,003 vs OLZ; +p < 0,001 vs OLZ and p = 0,003 vs RIS; ++p < 0,001 vs OLZBMC Psychiatry 2001, 1 http://www.biomedcentral.com/1471-244X/1/7
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had a positive subjective response at both the three and six
month time points compared to risperidone- and ha-
loperidol-treated patients. A significantly larger propor-
tion of risperidone-treated patients had a positive
subjective response at six months compared to haloperi-
dol-treated patients.
Treatment group rates of compliance as assessed by physi-
cian rating are detailed in Table 4. Olanzapine-treated pa-
tients were rated as significantly more compliant than
both risperidone- (p = 0.001) and haloperidol-treated (p
= 0.022) patients at six months.
Differences between olanzapine, risperidone and ha-
loperidol in subjective response by EPS category (presence
or absence of treatment emergent EPS) are shown in Table
5. DAI-10 scores were higher across all three treatment
groups for those patients who did not experience treat-
ment-emergent EPS. Olanzapine-treated patients had a
significantly better subjective response at six month time
points compared to risperidone-treated patients regard-
less of EPS category. Olanzapine-treated patients had a
significantly better subjective response than haloperidol-
treated patients in the treatment-emergent EPS subgroup.
There were no significant differences between olanzapine
and haloperidol with respect to subjective response in the
subgroup without EPS. Risperidone-treated patients had a
significantly better (p = 0.0015) subjective response rating
compared to haloperidol-treated patients in the subgroup
of patients with EPS but not in the subgroup without EPS
at month 6.
Discussion
The EFESO study is the first large prospective observation-
al study conducted with atypical antipsychotics, including
a control group, of which we are aware. Previous pub-
lished results from the EFESO study have shown that
olanzapine-treated patients have achieved superior out-
comes compared to patients treated with risperidone or
haloperidol [31,33,34]. Statistically significant findings
favouring olanzapine-treated patients compared to risp-
eridone- and/or haloperidol-treated patients have includ-
ed the proportion of patients who experienced at least one
adverse event, the percentage of patients who developed
EPS, and the proportion of responders at month six (olan-
zapine compared to risperidone). Risperidone is known
to induce EPS in a dose-dependent fashion and therefore,
results might have been different if risperidone had been
Table 3: Number and percentage of patients with a positive score in the DAI-10 by treatment group
OLZ RIS HAL
N = 2128 N = 417 N = 112
Baseline N 960 196 36
% 53,1 56,6 42,4*
3 months N 1458 259 58
% 82,3** 76,4 68,2
6 months N 1423 252 55
% 88,1+ 78++ 67,9
*p = 0,01 vs RIS; **p ≤  0,011 vs RIS and HAL; +p = 0,001 vs RIS and HAL; ++p = 0,05 vs HAL
Table 4: Compliance with principal antipsychotic treatment by treatment group. Percentage of patients at each compliance level.
OLZ RIS HAL p-value
3 months High 83,3 77,7 76,5 NS
Moderate 11,2 18,1 17,6
Low 3,8 3,6 4,9
Nil 1,7 0,5 1
6 months High 84,8 74,2 69,8 OLZ vs RIS, p = 0,001
Moderate 11,1 19,4 27,1 OLZ vs HAL, p = 0,022
Low 2,5 5 2,1
Nil 1,6 1,4 1BMC Psychiatry 2001, 1 http://www.biomedcentral.com/1471-244X/1/7
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lower. Nevertheless, risperidone dose in this study is con-
sistent with published reports from clinical practice [39].
The findings of the present analysis build on these previ-
ous findings. In this analysis, olanzapine was found to be
superior to both risperidone and haloperidol in terms of
subjective response and compliance. Further, subjective
response was significantly better in patients treated with
risperidone compared to patients treated with haloperi-
dol. The global incidence rate of adverse events and ex-
trapyramidal symptoms followed a similar pattern across
treatment groups, being greater for haloperidol and low-
est for olanzapine, with risperidone somewhere in the
middle [31]. This raises the issue of the potential relation-
ship between adverse events, particularly EPS, and pa-
tient's subjective response to antipsychotic treatment. This
fact would be in line with the opinion of some authors re-
garding the possibility that neuroleptic dysphoria is an af-
fective component in extrapyramidal effects or an element
in akathisia [16,17]. Thus, atypical drugs with a more fa-
vourable EPS profile, are thought to be associated with a
better subjective response than haloperidol or other con-
ventional drugs, perhaps not so much through the direct
mechanism of action but rather through the generation of
a lower rate of extrapyramidal effects.
It would seem reasonable to postulate that patients who
perceive the benefits of medication through the relief of
their symptoms and fewer unpleasant adverse events will
tend to have a more positive attitude, whereas those who
present highly incapacitating adverse events will not. The
DAI-10 was, to a large extent, designed to detect subjective
impact of EPS. Nevertheless, the results of our secondary
analyses suggest that EPS do not provide a full explana-
tion of the differences in subjective response between
treatments. DAI-10 scores were significantly higher in the
groups without EPS, regardless of antipsychotic treatment,
suggesting that EPS are a major contributor to negative
subjective responses. However, there were significant dif-
ferences between olanzapine- and risperidone-treated pa-
tients in terms of subjective response regardless of
whether patients exhibited EPS. This may indicate that dif-
ferences in EPS are not the sole explanation for differences
in subjective response. In the comparison between pa-
Table 5: DAI-10 score by treatment group and by presence/absence of EPS.
Patients with OLZ RIS HAL p-value
EPS N = 688 N = 189 N = 79
Baseline Mean 0,45 -0,36 -1,31 OLZ vs RIS, NS; OLZ 
vs HAL, 
p < 0,05; RIS vs HAL, 
NS
SD 5,12 5,27 5,16
Median 0 0 0
n of observations 667 184 72
6 months Mean 4,13 2,95 0,87 OLZ vs RIS, P = 
0,0031; OLZ vs HAL, 
p < 0,001; RIS vs HAL, 
P = 0,0015
SD 437 4,75 4,8
Median 6 4 2
n of observations 594 170 69
Patients OLZ RIS HAL p-value
without EPS N = 1175 N = 192 N = 25
Baseline Mean -0,02 0,82 -0,17 OLZ vs RIS, NS; OLZ 
vs HAL, NS; RIS vs 
HAL, NS
SD 5,51 5,19 5,72
Median 0 2 0
n of observations 1118 178 24
6 months Mean 4,9 3,85 4,42 OLZ vs RIS, p = 0,033; 
OLZ vs HAL, NS; RIS 
vs HAL, NS
SD 43 5,15 534
Median 6 6 6
n of observations 1128 183 24BMC Psychiatry 2001, 1 http://www.biomedcentral.com/1471-244X/1/7
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tients treated with olanzapine or risperidone versus ha-
loperidol, there were significant differences only in the
subgroup of patients who experienced EPS. The small
sample size of the subgroup of patients treated with ha-
loperidol and without EPS (N = 25) should be taken into
account in the interpretation of these data.
It is interesting to note that olanzapine treated patients
were rated as more compliant with treatment compared to
risperidone and haloperidol-treated patients. This finding
suggests a potential relationship between subjective re-
sponse and treatment compliance. Using different meas-
urement scales, other studies [1,35,2,25,26,19] have
highlighted the importance of subjective response in a
subject's decision to take antipsychotic medication. It
seems logical that how a patient feels and operates is go-
ing to influence future compliance [20]. Nevertheless, it is
important to take into account that compliance was meas-
ured in an exploratory fashion, using a scale that could
benefit from additional development and validation.
Therefore, definitive conclusions should not be drawn
from these results.
One should note that a larger proportion of olanzapine-
treated patients exhibited a positive subjective response
and clinical response to treatment [31] compared to both
risperidone- and haloperidol-treated patients. Differences
in clinical response may be linked to differences in subjec-
tive response. Singh, Smith and Kay [36,37] demonstrated
that poor clinical response was associated with a dysphor-
ic subjective response following administration of medi-
cation. Other studies have since confirmed these initial
findings [1,35], and subjective response has been identi-
fied as an indicator of initial response to antipsychotics
[38,13]. One should note, however, that these previous
studies have been focused on early (during the initial days
of treatment) subjective response, while we measured re-
sponse at 3 and 6 months of treatment. There is a recent
publication of a cross-sectional study that reports better
subjective response measured with the DAI-30 in patients
treated with new antipsychotics compared to convention-
al antipsychotics, but not difference between different
new antipsychotics (risperidone, olanzapine, quetiapine
and clozapine) [40].
When considering the results of the present analysis one
should consider the following methodologic limitations
associated with naturalistic studies: [1] selection bias sec-
ondary to lack of randomisation; [2] additional problems
in establishing unequivocal causal relationship due to fre-
quent use of concomitant medication; [3] difficulty in
keeping a strict control of the study because of the number
of participants, as shown by the majority of drop-outs be-
ing due to unknown reasons; and [4] unbalanced sample
size by treatment groups. Despite these limitations we feel
that our findings merit consideration when one is making
antipsychotic treatment choices, because the study closely
mimics the real-world clinical conditions Additional File.
Conclusions
This naturalistic study shows that subjective response and
compliance were better in patients treated with olanzap-
ine, compared to patients treated with risperidone and ha-
loperidol, in routine clinical practice. Subjective response
was also significantly better in patients treated with risp-
eridone compared to patients treated with haloperidol.
Differences in subjective response were explained largely,
but not completely, by differences in incidence of EPS.
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